Prognosis of testicular teratoma differentiated

Publisher Website
Google Scholar
Abstract
Objective To determine whether the clinical course of patients with testicular teratoma differentiated (TD) and those with testicular teratoma undifferentiated justify a different follow‐up protocol. Patients and methods Between 1979 and 1989, 16 adult patients with testicular TD were treated at the Royal Marsden Hospital. These represented 2.7% of the 592 testicular teratoma patients seen during this period. With the exception of a propensity to involve the right testis (76%), there were no differences in clinical presentation between TD and non‐TD histological subtypes. Results The mean follow‐up was 55 months (range 7–137). Seven of the 16 patients had Stage I disease and were entered into surveillance programmes; one relapsed at 7 months. Ten men were treated with cisplatin or carboplatin‐based chemotherapy for metastases, of whom three had had prior chemotherapy at other hospitals and were referred after relapse. In the seven previously‐untreated chemotherapy group two patients failed. In the concurrent era, 375 patients with other subtypes of metastatic testicular nonseminoma were treated with chemotherapy and 47 (12.5%) failed (Progress Free Survival chi square (ξ2) = 2.73, P= 0.01). Although no difference in progression‐free survival was demonstrated between TD and non‐TD patients, the former had a worse overall survival probability (ξ2= 9.02, P= 0.003); this may be an artefact due to the small number of events. Conclusion Despite the apparently more benign histology, it is recommended that the management of adult TD should not deviate from the general principles established for other histological subtypes of testicular teratoma.